These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 17190526)

  • 21. Neurotensin: role in psychiatric and neurological diseases.
    Cáceda R; Kinkead B; Nemeroff CB
    Peptides; 2006 Oct; 27(10):2385-404. PubMed ID: 16891042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The neurotensin agonist NT69L improves sensorimotor gating deficits in rats induced by a glutamatergic antagonist, but not by dopaminergic agonists.
    Secchi RL; Sung E; Hedley LR; Button D; Schreiber R
    Behav Brain Res; 2009 Sep; 202(2):192-7. PubMed ID: 19463701
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neurotensin agonists block the prepulse inhibition deficits produced by a 5-HT2A and an alpha1 agonist.
    Shilling PD; Melendez G; Priebe K; Richelson E; Feifel D
    Psychopharmacology (Berl); 2004 Sep; 175(3):353-9. PubMed ID: 15107967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A systemically administered neurotensin agonist blocks disruption of prepulse inhibition produced by a serotonin-2A agonist.
    Feifel D; Melendez G; Shilling PD
    Neuropsychopharmacology; 2003 Apr; 28(4):651-3. PubMed ID: 12655309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neurotensin-deficient mice show altered responses to antipsychotic drugs.
    Dobner PR; Fadel J; Deitemeyer N; Carraway RE; Deutch AY
    Proc Natl Acad Sci U S A; 2001 Jul; 98(14):8048-53. PubMed ID: 11427716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel pharmacological approaches to the treatment of schizophrenia.
    Fink-Jensen A
    Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurotensin, schizophrenia, and common sense.
    Skrabanek P
    Am J Psychiatry; 1983 May; 140(5):658. PubMed ID: 6133464
    [No Abstract]   [Full Text] [Related]  

  • 28. Evolution of schizophrenia drugs: a focus on dopaminergic systems.
    Nikam SS; Awasthi AK
    Curr Opin Investig Drugs; 2008 Jan; 9(1):37-46. PubMed ID: 18183530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neurotensin-like immunoreactivity in cerebrospinal fluid of patients with schizophrenia, depression, anorexia nervosa-bulimia, and premenstrual syndrome.
    Nemeroff CB; Bissette G; Widerlov E; Beckmann H; Gerner R; Manberg PJ; Lindstrom L; Prange AJ; Gattaz WF
    J Neuropsychiatry Clin Neurosci; 1989; 1(1):16-20. PubMed ID: 2577718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting neurotensin receptors with agonists and antagonists for therapeutic purposes.
    Kitabgi P
    Curr Opin Drug Discov Devel; 2002 Sep; 5(5):764-76. PubMed ID: 12630297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Striatal dopamine receptor plasticity in neurotensin deficient mice.
    Chastain LG; Qu H; Bourke CH; Iuvone PM; Dobner PR; Nemeroff CB; Kinkead B
    Behav Brain Res; 2015 Mar; 280():160-71. PubMed ID: 25449842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Neurotensin, dopamine and mode of action of neuroleptics].
    Tassin JP
    Encephale; 1989; 15(5):465-70. PubMed ID: 2574102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antipsychotic drug-like facilitation of latent inhibition by a brain-penetrating neurotensin-1 receptor agonist.
    Feifel D; Shilling PD; Fazlinejad AA; Melendez G
    J Psychopharmacol; 2016 Mar; 30(3):312-7. PubMed ID: 26783230
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neurobiological background for the development of new drugs in schizophrenia.
    López-Muñoz F; Álamo C
    Clin Neuropharmacol; 2011; 34(3):111-26. PubMed ID: 21586917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurotensin and dopamine interactions.
    Binder EB; Kinkead B; Owens MJ; Nemeroff CB
    Pharmacol Rev; 2001 Dec; 53(4):453-86. PubMed ID: 11734615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subnormal CSF levels of neurotensin in a subgroup of schizophrenic patients: normalization after neuroleptic treatment.
    Widerlöv E; Lindström LH; Besev G; Manberg PJ; Nemeroff CB; Breese GR; Kizer JS; Prange AJ
    Am J Psychiatry; 1982 Sep; 139(9):1122-6. PubMed ID: 6126127
    [No Abstract]   [Full Text] [Related]  

  • 37. Effects of acute and subchronic administration of typical and atypical antipsychotic drugs on the neurotensin system of the rat brain.
    Kinkead B; Shahid S; Owens MJ; Nemeroff CB
    J Pharmacol Exp Ther; 2000 Oct; 295(1):67-73. PubMed ID: 10991962
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of neurotensin in central nervous system pathophysiology: what is the evidence?
    St-Gelais F; Jomphe C; Trudeau LE
    J Psychiatry Neurosci; 2006 Jul; 31(4):229-45. PubMed ID: 16862241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of acute and subchronic d-amphetamine on ventral striatal concentrations of neurotensin and neuropeptide Y in rats treated with antipsychotic drugs.
    Gruber SH; Nomikos GG; Mathé AA
    Eur Neuropsychopharmacol; 2006 Dec; 16(8):592-600. PubMed ID: 16524702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of haloperidol and risperidone on neurotensin levels in brain regions and neurotensin efflux in the ventral striatum of the rat.
    Gruber SH; Nomikos GG; Mathé AA
    Neuropsychopharmacology; 2002 May; 26(5):595-604. PubMed ID: 11927184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.